Scarica l'app Stockscreener
3.51
2.93%
0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Agenus Inc Borsa (AGEN) Ultime notizie
Agenus (NASDAQ: AGEN) director Harrison awarded 8,547 shares as board compensation - Stock Titan
Form 4 Agenus Inc For: 7 July By Investing.com - Investing.com Canada
Director Wright of Agenus (NASDAQ: AGEN) granted deferred stock units - Stock Titan
Agenus Inc. Amends Notes and Issues New Warrants in 2026 Definitive Agreement – Key Details and Terms - Minichart
Agenus Extends $5.09M Notes to 2027, Lengthens Warrants to 2031 and Issues New D Warrants - TradingView
Agenus (NASDAQ: AGEN) extends note maturity and long-dated warrants - Stock Titan
Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI - Oncodaily
Agenus BOT+BAL Shows 33% Three-Year Survival in Immunotherapy-Resistant Colorectal Cancer - BioPharm International
BOT+BAL Continues to Show Durable Clinical Benefit in MSS mCRC – Agenus - Oncodaily
Agenus (AGEN) Reports Promising Data on BOT/BAL Therapy for Colo - GuruFocus
Agenus reports 3-year survival data in colorectal cancer study - grafa.com
Agenus Achieves 33% Three-Year Survival in Colorectal Cancer - AllSci
Agenus reports 3-year survival data for colorectal cancer therapy - Investing.com
Agenus (AGEN) Reports Promising Long-Term Survival Data for BOT+ - GuruFocus
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 - lincolnjournal.com
Form 4 Agenus Inc For: 30 June By Investing.com - Investing.com Australia
Agenus (AGEN) director Armen takes June 2026 salary in 5,364 company shares - Stock Titan
Agenus Inc.(NasdaqCM: AGEN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Index - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2500 Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Value Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Value Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Index - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Growth Benchmark - marketscreener.com
Durable Outcomes in MSS Metastatic Colorectal Cancer Without Active Liver MetastasesAgenus - Oncodaily
Price to sales forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Enterprise value to revenue forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Price to book forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Agenus Inc. Actuals & Estimates (BX:AGEN) - TradingView
Agenus Inc. Actuals & Estimates (NASDAQ:AGEN) - TradingView
AGEN Forecast — Price Target — Prediction for 2027 - TradingView
Agenus Inc. Actuals & Estimates (TRADEGATE:AJ8) - TradingView
Agenus to present 3-year cancer trial data at ESMO conference - Investing.com South Africa
Agenus Challenges 'Untreatable' Status of a Common Colorectal Cancer - BriefGlance
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 - BioSpace
Agenus (AGEN) Set to Present Promising Survival Data at ESMO 202 - GuruFocus
Agenus Announces Three-Year Survival Data From Phase 1B Bot+Bal Study In Mss Metastatic Colorectal Cancer To Be Presented At Esmo Gi 2026 - TradingView
Agenus Inc (AGEN) Institutional Confidence - TradingKey
Speed and Rigor Are Not in Conflict – Garo Armen - Oncodaily
Form 8K Agenus Inc For: 23 June By Investing.com - Investing.com Nigeria
Agenus Inc. Files Form 8-K with SEC: Corporate Details, Stock Information & Key Disclosures (June 16, 2026) 25 - Minichart
Agenus Shareholders Approve Governance, Compensation and Auditors - TipRanks
Form 8K Agenus Inc For: 23 June - Investing.com UK
Agenus (NASDAQ: AGEN) investors approve equity plan changes and KPMG - Stock Titan
Agenus Inc (AGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Agenus Inc (AGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agenus Inc (AGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agenus Inc (AGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agenus Inc (AGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AGEN Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Agenus Inc (AGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Agenus Inc (AGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Agenus Inc (AGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Are options traders betting on a big move in Agenus stock? - MSN
Agenus annual meeting: BOT/BAL leads cancer drug push as balance sheet improves - MSN
1.88%
2.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):